Skip to content
Screener
Fennec Pharmaceuticals logo

Fennec Pharmaceuticals

FENC

Fennec Pharmaceuticals is a commercial-stage specialty biotechnology company focused on preventing cisplatin-induced ototoxicity in pediatric cancer patients.

Market cap
$379.78M+75.4%

Earnings

Next report

Date not yet announced

Competitors

Profile

Fennec Pharmaceuticals is a commercial-stage specialty biotechnology company focused on preventing cisplatin-induced ototoxicity in pediatric cancer patients. Its core value proposition is providing the first and only regulatory-approved therapy to reduce the risk of permanent hearing loss associated with platinum-based chemotherapy. The company operates as a virtual manufacturer, leveraging third-party partnerships for production and international commercialization.

Competitive position

Fennec holds a first-mover advantage as the provider of the only FDA and EMA-approved treatment for cisplatin-induced hearing loss in its specific pediatric indication.

GeographiesUnited States, Europe, United Kingdom, Australia, New Zealand, Turkey, Gulf Cooperation Council
Customer segmentsHospitals, Oncology Networks, Specialty Pharmacies
Business modelB2B, Licensing, Virtual Manufacturing
SuppliersAPI suppliers, Contract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs)
CustomersPediatric oncology specialists, Group Purchasing Organizations (GPOs), Specialty pharmacies, Government and private health insurers
Listed2002
Employees29.0
CEOJeffrey S. Hackman
FilingsSEC EDGAR

FAQ

What is Fennec Pharmaceuticals's market cap?
Fennec Pharmaceuticals (FENC) has a market capitalization of $379.8M and trades on NASDAQ.
Who are Fennec Pharmaceuticals's competitors?
Fennec Pharmaceuticals's key competitors include TriSalus Life Sciences, Inc. Common Stock, NovoCure Limited Ordinary Shares, Spruce Biosciences, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Fennec Pharmaceuticals partner with?
Fennec Pharmaceuticals's notable partners include Norgine, Inpharmus, City of Hope, and others.
What subsidiaries does Fennec Pharmaceuticals have?
Fennec Pharmaceuticals's subsidiaries include Fennec Pharmaceuticals, Inc. (Delaware), Fennec Pharmaceuticals (EU) Limited, Oxiquant, Inc., and others.
Where is Fennec Pharmaceuticals headquartered?
Fennec Pharmaceuticals is headquartered in United States of America and employs approximately 29 people. It has been publicly traded since 2002.